Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02049801 · ClinicalTrials.gov registry record · Phase 1
MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
A Phase 1 study, sponsored by Bruno C. Medeiros.
- Terminated
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT02049801 is a Phase 1 study that was terminated before completion, run by Bruno C. Medeiros. The registered enrollment target is 1 participants.
The verdict
NCT02049801, a Phase 1 study, was terminated before completion, sponsored by Bruno C. Medeiros.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
This phase I trial studies the MEK inhibitor MEK162 to see if it is safe in patients when combined with idarubicin and cytarabine. MEK inhibitor MEK162 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as idarubicin and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving MEK inhibitor MEK162, cytarabine, and idarubicin may be an effective treatment for acute myeloid leukemia.
Interventions
- OTHER laboratory biomarker analysis
- OTHER pharmacological study
- DRUG cytarabine
- DRUG idarubicin
- DRUG MEK inhibitor MEK162
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2014-12 |
| Est. Completion | 2017-11-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02049801
The ClinicalTrials.gov registry entry for NCT02049801 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bruno C. Medeiros, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which laboratory biomarker analysis is the first listed.
NCT02049801 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02049801 about?
NCT02049801 is a clinical study titled "MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia". This phase I trial studies the MEK inhibitor MEK162 to see if it is safe in patients when combined with idarubicin and cytarabine. MEK inhibitor MEK162 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as idarubicin and cytar...
What is the current status of trial NCT02049801?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2014-12. Estimated completion is 2017-11-01.
What interventions are being tested in trial NCT02049801?
The interventions under investigation include: laboratory biomarker analysis (OTHER), pharmacological study (OTHER), cytarabine (DRUG), idarubicin (DRUG), MEK inhibitor MEK162 (DRUG).
Who is sponsoring clinical trial NCT02049801?
This trial is sponsored by Bruno C. Medeiros, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.